Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease

By Heydorn W.E.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 10, 1997-10 ,pp. : 1527-1537

Informa Healthcare

Access to resources Recommend Favorite

Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer’s disease

By Cummings J.L.   Ringman J.M.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 463-471

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

By Gottwald M.D.   Rozanski R.I.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1673-1682

Informa Healthcare

Access to resources Recommend Favorite

A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer 's Disease, in Healthy Subjects and Patients

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs

By Cousins M.S.   Carriero D.L.   Salamone J.D.  

European Journal of Pharmacology, Vol. 322, Iss. 2, 1997-03 ,pp. : 137-145

Elsevier

Access to resources Recommend Favorite